2023-10-04 10:40:41
INTERCEPT PHARMACEUTICALS, INC. (747-304) – Latin Clinical Trial Center

INTERCEPT PHARMACEUTICALS, INC. (747-304)

By June 19, 2019 Active/Enrolling
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis

Join the discussion 8 Comments

Leave a Reply